Uttley, Lesley http://orcid.org/0000-0003-4603-9069
Bermejo, Iñigo
Ren, Shijie
Martyn-St James, Marrissa
Wong, Ruth
Scott, David L.
Young, Adam
Stevenson, Matt
Funding for this research was provided by:
Health Technology Assessment Programme (19/04/17)
Article History
First Online: 15 March 2018
Compliance with Ethical Standards
:
: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (Project Number 19/04/17). Visit the HTA programme website for further project information (ExternalRef removed).
: David Scott has no conflicts of interest relating to tofacitinib. However, his department has received a peer-reviewed grant from Pfizer within the last 12 months to undertake academic research on polypharmacy in arthritis. The department has also received free etanercept from Pfizer to use in an NIHR-funded programme grant in rheumatoid arthritis. David Scott and Matt Stevenson declare that they have written a commentary on janus kinase inhibitors forThe Lancet(ExternalRef removed).The Lanceteditorial was written after the completion of this STA. Lesley Uttley, Iñigo Bermejo, Shijie Ren, Marrissa Martyn-St James, Ruth Wong and Adam Young have no conflicts of interest to declare.